Search

Your search keyword '"Rizos, Helen"' showing total 611 results
Start Over Author "Rizos, Helen"
611 results on '"Rizos, Helen"'

9. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

Author

Menzies, Alexander M., primary, Lo, Serigne N., additional, Saw, Robyn P.M., additional, Gonzalez, Maria, additional, Ch’ng, Sydney, additional, Nieweg, Omgo E., additional, Shannon, Kerwin F., additional, Ferguson, Peter M., additional, Lee, Jenny, additional, Emmett, Louise, additional, Kapoor, Rony, additional, Rawson, Robert V., additional, Stretch, Jonathan R., additional, Thompson, John F., additional, Spillane, Andrew J., additional, Rizos, Helen, additional, Scolyer, Richard A., additional, and Long, Georgina V., additional

Published
2024
Full Text
View/download PDF

11. Biology of Melanocytes and Primary Melanoma

Author

Zaidi, M. Raza, Fisher, David E., Rizos, Helen, Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

14. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Author

Johnson, Douglas B, Menzies, Alexander M, Zimmer, Lisa, Eroglu, Zeynep, Ye, Fei, Zhao, Shilin, Rizos, Helen, Sucker, Antje, Scolyer, Richard A, Gutzmer, Ralf, Gogas, Helen, Kefford, Richard F, Thompson, John F, Becker, Jürgen C, Berking, Carola, Egberts, Friederike, Loquai, Carmen, Goldinger, Simone M, Pupo, Gulietta M, Hugo, Willy, Kong, Xiangju, Garraway, Levi A, Sosman, Jeffrey A, Ribas, Antoni, Lo, Roger S, Long, Georgina V, and Schadendorf, Dirk

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Genetics, Clinical Research, 2.1 Biological and endogenous factors, Aetiology, Antineoplastic Agents, Australia, Biomarkers, Tumor, DNA Mutational Analysis, Disease Progression, Disease-Free Survival, Drug Resistance, Neoplasm, Europe, Female, Genetic Predisposition to Disease, Humans, Kaplan-Meier Estimate, Male, Melanoma, Middle Aged, Mutation, Phenotype, Proportional Hazards Models, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Risk Factors, Signal Transduction, Skin Neoplasms, Time Factors, Treatment Outcome, United States, BRAF, Vemurafenib, Dabrafenib, Resistance, Acquired, MAPK, NRAS, Splice, MEK1, Meta-analysis, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundAcquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon caused by numerous genetic and non-genetic alterations. In this study, we evaluated the spectrum, onset, pattern of progression, and subsequent clinical outcomes associated with specific mechanisms of resistance.MethodsWe compiled clinical and genetic data from 100 patients with 132 tissue samples obtained at progression on BRAFi therapy from 3 large, previously published studies of BRAFi resistance. These samples were subjected to whole-exome sequencing and/or polymerase chain reaction-based genetic testing.ResultsAmong 132 samples, putative resistance mechanisms were identified in 58%, including NRAS or KRAS mutations (20%), BRAF splice variants (16%), BRAF(V600E/K) amplifications (13%), MEK1/2 mutations (7%), and non-mitogen-activated protein kinase pathway alterations (11%). Marked heterogeneity was observed within tumors and patients; 18 of 19 patients (95%) with more than one progression biopsy had distinct/unknown drivers of resistance between samples. NRAS mutations were associated with vemurafenib use (p = 0.045) and intracranial metastases (p = 0.036), and MEK1/2 mutations correlated with hepatic progression (p = 0.011). Progression-free survival and overall survival were similar across resistance mechanisms. The median survival after disease progression was 6.9 months, and responses to subsequent BRAF and MEK inhibition were uncommon (2 of 15; 13%). Post-progression outcomes did not correlate with specific acquired BRAFi-resistance mechanisms.ConclusionsThis is the first study to systematically characterise the clinical implications of particular acquired BRAFi-resistance mechanisms in patients with BRAF-mutant melanoma largest study to compile the landscape of resistance. Despite marked heterogeneity of resistance mechanisms within patients, NRAS mutations correlated with vemurafenib use and intracranial disease involvement.

Published
2015

15. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Author

Andrews, Miles C, Berry, Donald A, Block, Matthew S, Boland, Genevieve M, Bollin, Kathryn B, Carlino, Matteo S, Carvajal, Richard D, Cohen, Jonathan, Davar, Diwakar, Delman, Keith A, Dummer, Reinhard, Farwell, Michael D, Fisher, David E, Fusi, Alberto, Glitza, Isabella C, de Gruijl, Tanja D, Gyorki, David E, Hauschild, Axel, Hieken, Tina J, Larkin, James, Lawson, David H, Lebbe, Celeste, Lee, Jeffrey E, Lowe, Michael C, Luke, Jason J, McArthur, Grant A, McDermott, David F, McQuade, Jennifer L, Mitchell, Tara C, Petrella, Teresa M, Prieto, Peter A, Puzanov, Igor, Robert, Caroline, Salama, April K, Sandhu, Shaneen, Schadendorf, Dirk, Shoushtari, Alexander N, Sosman, Jeffrey A, Swetter, Susan M, Tanabe, Ken K, Turajlic, Samra, Tyler, Douglas S, Woodman, Scott E, Wright, Frances C, Zager, Jonathan S, Amaria, Rodabe N, Menzies, Alexander M, Burton, Elizabeth M, Scolyer, Richard A, Tetzlaff, Michael T, Antdbacka, Robert, Ariyan, Charlotte, Bassett, Roland, Carter, Brett, Daud, Adil, Faries, Mark, Fecher, Leslie A, Flaherty, Keith T, Gershenwald, Jeffrey E, Hamid, Omid, Hong, Angela, Kirkwood, John M, Lo, Serigne, Margolin, Kim, Messina, Jane, Postow, Michael A, Rizos, Helen, Ross, Merrick I, Rozeman, Elisa A, Saw, Robyn P M, Sondak, Vernon, Sullivan, Ryan J, Taube, Janis M, Thompson, John F, van de Wiel, Bart A, Eggermont, Alexander M, Davies, Michael A, Ascierto, Paolo A, Spillane, Andrew J, van Akkooi, Alexander C J, Wargo, Jennifer A, Blank, Christian U, Tawbi, Hussein A, and Long, Georgina V

Published
2019
Full Text
View/download PDF

16. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Author

Long, Georgina V, Saw, Robyn P M, Lo, Serigne, Nieweg, Omgo E, Shannon, Kerwin F, Gonzalez, Maria, Guminski, Alexander, Lee, Jenny H, Lee, Hansol, Ferguson, Peter M, Rawson, Robert V, Wilmott, James S, Thompson, John F, Kefford, Richard F, Ch'ng, Sydney, Stretch, Jonathan R, Emmett, Louise, Kapoor, Rony, Rizos, Helen, Spillane, Andrew J, Scolyer, Richard A, and Menzies, Alexander M

Published
2019
Full Text
View/download PDF

18. Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Author

Parmenter, Tiffany J, Kleinschmidt, Margarete, Kinross, Kathryn M, Bond, Simon T, Li, Jason, Kaadige, Mohan R, Rao, Aparna, Sheppard, Karen E, Hugo, Willy, Pupo, Gulietta M, Pearson, Richard B, McGee, Sean L, Long, Georgina V, Scolyer, Richard A, Rizos, Helen, Lo, Roger S, Cullinane, Carleen, Ayer, Donald E, Ribas, Antoni, Johnstone, Ricky W, Hicks, Rodney J, and McArthur, Grant A

Subjects
Clinical Research, Genetics, Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Cell Line, Tumor, Drug Resistance, Neoplasm, Glycolysis, HEK293 Cells, Humans, Indoles, MAP Kinase Signaling System, Melanoma, Piperazines, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Pyridines, Sulfonamides, Transcription Factors, Vemurafenib, Oncology and Carcinogenesis
Abstract

UnlabelledDeregulated glucose metabolism fulfills the energetic and biosynthetic requirements for tumor growth driven by oncogenes. Because inhibition of oncogenic BRAF causes profound reductions in glucose uptake and a strong clinical benefit in BRAF-mutant melanoma, we examined the role of energy metabolism in responses to BRAF inhibition. We observed pronounced and consistent decreases in glycolytic activity in BRAF-mutant melanoma cells. Moreover, we identified a network of BRAF-regulated transcription factors that control glycolysis in melanoma cells. Remarkably, this network of transcription factors, including hypoxia-inducible factor-1α, MYC, and MONDOA (MLXIP), drives glycolysis downstream of BRAF(V600), is critical for responses to BRAF inhibition, and is modulated by BRAF inhibition in clinical melanoma specimens. Furthermore, we show that concurrent inhibition of BRAF and glycolysis induces cell death in BRAF inhibitor (BRAFi)-resistant melanoma cells. Thus, we provide a proof-of-principle for treatment of melanoma with combinations of BRAFis and glycolysis inhibitors.SignificanceBRAF is suppress glycolysis and provide strong clinical benefi t in BRAF V600 melanoma. We show that BRAF inhibition suppresses glycolysis via a network of transcription factors that are critical for complete BRAFi responses. Furthermore, we provide evidence for the clinical potential of therapies that combine BRAFis with glycolysis inhibitors.

Published
2014

19. Ex vivo tissue modelling informs drug selection for rare cancers.

Author

Lee, Jenny H., Ming, Zizhen, Cheung, Veronica K. Y., Pedersen, Bernadette, Wykes, James J., Palme, Carsten E., Clark, Jonathan J., Gupta, Ruta, and Rizos, Helen

Subjects
THYROID cancer, INDIVIDUALIZED medicine, GENETIC mutation, TISSUES, GENE targeting, DRUGS
Abstract

The identification and therapeutic targeting of actionable gene mutations across many cancer types has resulted in improved response rates in a minority of patients. The identification of actionable mutations is usually not sufficient to ensure complete nor durable responses, and in rare cancers, where no therapeutic standard of care exists, precision medicine indications are often based on pan‐cancer data. The inclusion of functional data, however, can provide evidence of oncogene dependence and guide treatment selection based on tumour genetic data. We applied an ex vivo cancer explant modelling approach, that can be embedded in routine clinical care and allows for pathological review within 10 days of tissue collection. We now report that ex vivo tissue modelling provided accurate longitudinal response data in a patient with BRAFV600E‐mutant papillary thyroid tumour with squamous differentiation. The ex vivo model guided treatment selection for this patient and confirmed treatment resistance when the patient's disease progressed after 8 months of treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Senescence

Author

Rizos, Helen, Haferkamp, Sebastian, Scurr, Lyndee L., and Bosserhoff, Anja K., editor

Published
2017
Full Text
View/download PDF

26. Supplementary Figure S1 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Author

Lee, Hansol, primary, Ferguson, Angela L., primary, Quek, Camelia, primary, Vergara, Ismael A., primary, Pires daSilva, Ines, primary, Allen, Ruth, primary, Gide, Tuba Nur, primary, Conway, Jordan W., primary, Koufariotis, Lambros T., primary, Hayward, Nicholas K., primary, Waddell, Nicola, primary, Carlino, Matteo S., primary, Menzies, Alexander M., primary, Saw, Robyn P.M., primary, Shklovskaya, Elena, primary, Rizos, Helen, primary, Lo, Serigne, primary, Scolyer, Richard A., primary, Long, Georgina V., primary, Palendira, Umaimainthan, primary, and Wilmott, James S., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table S1 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Author

Lee, Hansol, primary, Ferguson, Angela L., primary, Quek, Camelia, primary, Vergara, Ismael A., primary, Pires daSilva, Ines, primary, Allen, Ruth, primary, Gide, Tuba Nur, primary, Conway, Jordan W., primary, Koufariotis, Lambros T., primary, Hayward, Nicholas K., primary, Waddell, Nicola, primary, Carlino, Matteo S., primary, Menzies, Alexander M., primary, Saw, Robyn P.M., primary, Shklovskaya, Elena, primary, Rizos, Helen, primary, Lo, Serigne, primary, Scolyer, Richard A., primary, Long, Georgina V., primary, Palendira, Umaimainthan, primary, and Wilmott, James S., primary

Published
2023
Full Text
View/download PDF

28. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours

Author

Johansson, Peter A., Brooks, Kelly, Newell, Felicity, Palmer, Jane M., Wilmott, James S., Pritchard, Antonia L., Broit, Natasa, Wood, Scott, Carlino, Matteo S., Leonard, Conrad, Koufariotis, Lambros T., Nathan, Vaishnavi, Beasley, Aaron B., Howlie, Madeleine, Dawson, Rebecca, Rizos, Helen, Schmidt, Chris W., Long, Georgina V., Hamilton, Hayley, Kiilgaard, Jens F., Isaacs, Timothy, Gray, Elin S., Rolfe, Olivia J., Park, John J., Stark, Andrew, Mann, Graham J., Scolyer, Richard A., Pearson, John V., van Baren, Nicolas, Waddell, Nicola, Wadt, Karin W., McGrath, Lindsay A., Warrier, Sunil K., Glasson, William, and Hayward, Nicholas K.

Published
2020
Full Text
View/download PDF

30. Checkpoint kinase 1 inhibitor + low‐dose hydroxyurea efficiently kills BRAF inhibitor‐ and immune checkpoint inhibitor‐resistant melanomas.

Author

Zeng, Zhen, Ngo, Hung Long, Proctor, Martina, Rizos, Helen, Dolcetti, Riccardo, Cruz, Jazmina Gonzalez, Wells, James W., and Gabrielli, Brian

Subjects
CHECKPOINT kinase 1, IMMUNE checkpoint proteins, KINASE inhibitors, BRAF genes, IMMUNE checkpoint inhibitors
Abstract

Treatment of melanomas with targeted and immunotherapies has proven effective, but resistance to both treatments is a common outcome leaving a high proportion of patients without effective alternative treatment options. Replication stress is a common feature of melanomas, and this is effectively targeted using a combination of checkpoint kinase 1 (CHK1) inhibitor and low‐dose hydroxyurea (LDHU). This combination also promotes inflammatory and anti‐tumour immune responses in vivo. Melanoma cell lines resistant to BRAF inhibitor (BRAFi) or immune checkpoint inhibitors (ICI) retain their sensitivity to CHK1i + LDHU, with sensitivity similar to that of parental tumours. In vivo, BRAFi‐resistant and BRAFi‐sensitive parental tumours produce an identical immune response with treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Data from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

Author

Eskiocak, Banu, primary, McMillan, Elizabeth A., primary, Mendiratta, Saurabh, primary, Kollipara, Rahul K., primary, Zhang, Hailei, primary, Humphries, Caroline G., primary, Wang, Changguang, primary, Garcia-Rodriguez, Jose, primary, Ding, Ming, primary, Zaman, Aubhishek, primary, Rosales, Tracy I., primary, Eskiocak, Ugur, primary, Smith, Michael P., primary, Sudderth, Jessica, primary, Komurov, Kakajan, primary, Deberardinis, Ralph J., primary, Wellbrock, Claudia, primary, Davies, Michael A., primary, Wargo, Jennifer A., primary, Yu, Yonghao, primary, De Brabander, Jef K., primary, Williams, Noelle S., primary, Chin, Lynda, primary, Rizos, Helen, primary, Long, Georgina V., primary, Kittler, Ralf, primary, and White, Michael A., primary

Published
2023
Full Text
View/download PDF

33. Figure S2 from Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma

Author

Zhang, Xiaomeng, primary, Tang, Jian Zhong, primary, Vergara, Ismael A., primary, Zhang, Youfang, primary, Szeto, Pacman, primary, Yang, Lie, primary, Mintoff, Christopher, primary, Colebatch, Andrew, primary, McIntosh, Lachlan, primary, Mitchell, Katrina A., primary, Shaw, Evangeline, primary, Rizos, Helen, primary, Long, Georgina V., primary, Hayward, Nicholas, primary, McArthur, Grant A., primary, Papenfuss, Anthony T., primary, Harvey, Kieran F., primary, and Shackleton, Mark, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Data 2 from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Author

Parmenter, Tiffany J., primary, Kleinschmidt, Margarete, primary, Kinross, Kathryn M., primary, Bond, Simon T., primary, Li, Jason, primary, Kaadige, Mohan R., primary, Rao, Aparna, primary, Sheppard, Karen E., primary, Hugo, Willy, primary, Pupo, Gulietta M., primary, Pearson, Richard B., primary, McGee, Sean L., primary, Long, Georgina V., primary, Scolyer, Richard A., primary, Rizos, Helen, primary, Lo, Roger S., primary, Cullinane, Carleen, primary, Ayer, Donald E., primary, Ribas, Antoni, primary, Johnstone, Ricky W., primary, Hicks, Rodney J., primary, and McArthur, Grant A., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Tables S1-S15 from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

Author

Eskiocak, Banu, primary, McMillan, Elizabeth A., primary, Mendiratta, Saurabh, primary, Kollipara, Rahul K., primary, Zhang, Hailei, primary, Humphries, Caroline G., primary, Wang, Changguang, primary, Garcia-Rodriguez, Jose, primary, Ding, Ming, primary, Zaman, Aubhishek, primary, Rosales, Tracy I., primary, Eskiocak, Ugur, primary, Smith, Michael P., primary, Sudderth, Jessica, primary, Komurov, Kakajan, primary, Deberardinis, Ralph J., primary, Wellbrock, Claudia, primary, Davies, Michael A., primary, Wargo, Jennifer A., primary, Yu, Yonghao, primary, De Brabander, Jef K., primary, Williams, Noelle S., primary, Chin, Lynda, primary, Rizos, Helen, primary, Long, Georgina V., primary, Kittler, Ralf, primary, and White, Michael A., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 3 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma

Author

Carlino, Matteo S., primary, Gowrishankar, Kavitha, primary, Saunders, Catherine A.B., primary, Pupo, Gulietta M., primary, Snoyman, Stephanie, primary, Zhang, Xu Dong, primary, Saw, Robyn, primary, Becker, Therese M., primary, Kefford, Richard F., primary, Long, Georgina V., primary, and Rizos, Helen, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 1 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma

Author

Carlino, Matteo S., primary, Gowrishankar, Kavitha, primary, Saunders, Catherine A.B., primary, Pupo, Gulietta M., primary, Snoyman, Stephanie, primary, Zhang, Xu Dong, primary, Saw, Robyn, primary, Becker, Therese M., primary, Kefford, Richard F., primary, Long, Georgina V., primary, and Rizos, Helen, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Text, Figure Legends, Figures S1-S12 from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

Author

Eskiocak, Banu, primary, McMillan, Elizabeth A., primary, Mendiratta, Saurabh, primary, Kollipara, Rahul K., primary, Zhang, Hailei, primary, Humphries, Caroline G., primary, Wang, Changguang, primary, Garcia-Rodriguez, Jose, primary, Ding, Ming, primary, Zaman, Aubhishek, primary, Rosales, Tracy I., primary, Eskiocak, Ugur, primary, Smith, Michael P., primary, Sudderth, Jessica, primary, Komurov, Kakajan, primary, Deberardinis, Ralph J., primary, Wellbrock, Claudia, primary, Davies, Michael A., primary, Wargo, Jennifer A., primary, Yu, Yonghao, primary, De Brabander, Jef K., primary, Williams, Noelle S., primary, Chin, Lynda, primary, Rizos, Helen, primary, Long, Georgina V., primary, Kittler, Ralf, primary, and White, Michael A., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Methods from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

Author

Eskiocak, Banu, primary, McMillan, Elizabeth A., primary, Mendiratta, Saurabh, primary, Kollipara, Rahul K., primary, Zhang, Hailei, primary, Humphries, Caroline G., primary, Wang, Changguang, primary, Garcia-Rodriguez, Jose, primary, Ding, Ming, primary, Zaman, Aubhishek, primary, Rosales, Tracy I., primary, Eskiocak, Ugur, primary, Smith, Michael P., primary, Sudderth, Jessica, primary, Komurov, Kakajan, primary, Deberardinis, Ralph J., primary, Wellbrock, Claudia, primary, Davies, Michael A., primary, Wargo, Jennifer A., primary, Yu, Yonghao, primary, De Brabander, Jef K., primary, Williams, Noelle S., primary, Chin, Lynda, primary, Rizos, Helen, primary, Long, Georgina V., primary, Kittler, Ralf, primary, and White, Michael A., primary

Published
2023
Full Text
View/download PDF

40. Data from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Author

Parmenter, Tiffany J., primary, Kleinschmidt, Margarete, primary, Kinross, Kathryn M., primary, Bond, Simon T., primary, Li, Jason, primary, Kaadige, Mohan R., primary, Rao, Aparna, primary, Sheppard, Karen E., primary, Hugo, Willy, primary, Pupo, Gulietta M., primary, Pearson, Richard B., primary, McGee, Sean L., primary, Long, Georgina V., primary, Scolyer, Richard A., primary, Rizos, Helen, primary, Lo, Roger S., primary, Cullinane, Carleen, primary, Ayer, Donald E., primary, Ribas, Antoni, primary, Johnstone, Ricky W., primary, Hicks, Rodney J., primary, and McArthur, Grant A., primary

Published
2023
Full Text
View/download PDF

41. Data from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma

Author

Carlino, Matteo S., primary, Gowrishankar, Kavitha, primary, Saunders, Catherine A.B., primary, Pupo, Gulietta M., primary, Snoyman, Stephanie, primary, Zhang, Xu Dong, primary, Saw, Robyn, primary, Becker, Therese M., primary, Kefford, Richard F., primary, Long, Georgina V., primary, and Rizos, Helen, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data 1 from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Author

Parmenter, Tiffany J., primary, Kleinschmidt, Margarete, primary, Kinross, Kathryn M., primary, Bond, Simon T., primary, Li, Jason, primary, Kaadige, Mohan R., primary, Rao, Aparna, primary, Sheppard, Karen E., primary, Hugo, Willy, primary, Pupo, Gulietta M., primary, Pearson, Richard B., primary, McGee, Sean L., primary, Long, Georgina V., primary, Scolyer, Richard A., primary, Rizos, Helen, primary, Lo, Roger S., primary, Cullinane, Carleen, primary, Ayer, Donald E., primary, Ribas, Antoni, primary, Johnstone, Ricky W., primary, Hicks, Rodney J., primary, and McArthur, Grant A., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Methods from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Author

Parmenter, Tiffany J., primary, Kleinschmidt, Margarete, primary, Kinross, Kathryn M., primary, Bond, Simon T., primary, Li, Jason, primary, Kaadige, Mohan R., primary, Rao, Aparna, primary, Sheppard, Karen E., primary, Hugo, Willy, primary, Pupo, Gulietta M., primary, Pearson, Richard B., primary, McGee, Sean L., primary, Long, Georgina V., primary, Scolyer, Richard A., primary, Rizos, Helen, primary, Lo, Roger S., primary, Cullinane, Carleen, primary, Ayer, Donald E., primary, Ribas, Antoni, primary, Johnstone, Ricky W., primary, Hicks, Rodney J., primary, and McArthur, Grant A., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 2 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma

Author

Carlino, Matteo S., primary, Gowrishankar, Kavitha, primary, Saunders, Catherine A.B., primary, Pupo, Gulietta M., primary, Snoyman, Stephanie, primary, Zhang, Xu Dong, primary, Saw, Robyn, primary, Becker, Therese M., primary, Kefford, Richard F., primary, Long, Georgina V., primary, and Rizos, Helen, primary

Published
2023
Full Text
View/download PDF

45. Supplemental Legends from Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma

Author

Zhang, Xiaomeng, primary, Tang, Jian Zhong, primary, Vergara, Ismael A., primary, Zhang, Youfang, primary, Szeto, Pacman, primary, Yang, Lie, primary, Mintoff, Christopher, primary, Colebatch, Andrew, primary, McIntosh, Lachlan, primary, Mitchell, Katrina A., primary, Shaw, Evangeline, primary, Rizos, Helen, primary, Long, Georgina V., primary, Hayward, Nicholas, primary, McArthur, Grant A., primary, Papenfuss, Anthony T., primary, Harvey, Kieran F., primary, and Shackleton, Mark, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figures and Tables from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Author

Parmenter, Tiffany J., primary, Kleinschmidt, Margarete, primary, Kinross, Kathryn M., primary, Bond, Simon T., primary, Li, Jason, primary, Kaadige, Mohan R., primary, Rao, Aparna, primary, Sheppard, Karen E., primary, Hugo, Willy, primary, Pupo, Gulietta M., primary, Pearson, Richard B., primary, McGee, Sean L., primary, Long, Georgina V., primary, Scolyer, Richard A., primary, Rizos, Helen, primary, Lo, Roger S., primary, Cullinane, Carleen, primary, Ayer, Donald E., primary, Ribas, Antoni, primary, Johnstone, Ricky W., primary, Hicks, Rodney J., primary, and McArthur, Grant A., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 6 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma

Author

Carlino, Matteo S., primary, Gowrishankar, Kavitha, primary, Saunders, Catherine A.B., primary, Pupo, Gulietta M., primary, Snoyman, Stephanie, primary, Zhang, Xu Dong, primary, Saw, Robyn, primary, Becker, Therese M., primary, Kefford, Richard F., primary, Long, Georgina V., primary, and Rizos, Helen, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure Legend from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma

Author

Carlino, Matteo S., primary, Gowrishankar, Kavitha, primary, Saunders, Catherine A.B., primary, Pupo, Gulietta M., primary, Snoyman, Stephanie, primary, Zhang, Xu Dong, primary, Saw, Robyn, primary, Becker, Therese M., primary, Kefford, Richard F., primary, Long, Georgina V., primary, and Rizos, Helen, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 5 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma

Author

Carlino, Matteo S., primary, Gowrishankar, Kavitha, primary, Saunders, Catherine A.B., primary, Pupo, Gulietta M., primary, Snoyman, Stephanie, primary, Zhang, Xu Dong, primary, Saw, Robyn, primary, Becker, Therese M., primary, Kefford, Richard F., primary, Long, Georgina V., primary, and Rizos, Helen, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 4 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma

Author

Carlino, Matteo S., primary, Gowrishankar, Kavitha, primary, Saunders, Catherine A.B., primary, Pupo, Gulietta M., primary, Snoyman, Stephanie, primary, Zhang, Xu Dong, primary, Saw, Robyn, primary, Becker, Therese M., primary, Kefford, Richard F., primary, Long, Georgina V., primary, and Rizos, Helen, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results